[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"large-vessel-occlusion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:large-vessel-occlusion":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,47,77,104,129,164,192,214,240,264,288,314,342,365,389,411,433,454,479,504,527,554,576],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100635432","sivelestat-sodium-as-an-adjunct-to-endovascular-thrombectomy-for-acute-anterior-circulation-large-vessel-occlusion-100635432",false,"NCT07552610","Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy for Acute Anterior Circulation Large-Vessel Occlusion","Efficacy and Safety of Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy in Acute Anterior Circulation Large-Vessel Occlusion: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study","Inclusion Criteria:\n\n* 1.Symptoms and signs consistent with focal ischemia in the anterior circulation;\n* 2.Large vessel occlusion of the anterior circulation (internal carotid artery, M1\u002FM2 segment of the middle cerebral artery) confirmed by CTA\u002FMRA\u002FDSA;\n* 3.Undergoing mechanical thrombectomy;\n* 4.Age between 18-80 years, both male and female;\n* 5.Pre-stroke modified Rankin Scale (mRS) score ≤1;\n* 6.Time from symptom onset to thrombectomy ≤24 hours, including wake-up stroke or unwitnessed stroke; symptom onset is defined as the \"last known well\" (LKW);\n* 7.National Institutes of Health Stroke Scale (NIHSS) score ≥6 at admission;\n* 8.ASPECTS ≥3 for anterior circulation occlusion;\n* 9.Written informed consent provided by the patient or their legal representative.\n\nExclusion Criteria:\n\n* 1．Simultaneous acute occlusion of both the anterior and posterior circulation, or bilateral acute large-vessel occlusion in the anterior circulation;\n* 2．Failure to obtain a baseline NIHSS score before sedation or intubation by a neurologist or emergency physician;\n* 3．Seizure at stroke onset that precludes assessment of the baseline NIHSS score;\n* 4．Bilateral dilated pupils;\n* 5．Known allergy to sivelestat sodium or any of its excipients;\n* 6．Severe allergy or absolute contraindication to iodinated contrast agents;\n* 7．Systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg that cannot be controlled with antihypertensive therapy;\n* 8．Blood glucose \\\u003C50 mg\u002FdL (2.8 mmol\u002FL) or \\>400 mg\u002FdL (22.2 mmol\u002FL);\n* 9．Platelet count \\\u003C50 \\* 10⁹\u002FL;\n* 10．Hereditary or acquired bleeding tendency, coagulation factor deficiency, current oral anticoagulant use with INR \\>1.7, or oral anticoagulant treatment within the previous 48 hours;\n* 11．Severe renal failure, defined as serum creatinine \\>3.0 mg\u002FdL (265.2 μmol\u002FL), glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin, or requirement for hemodialysis or peritoneal dialysis;\n* 12．Inability to complete the 90-day follow-up (e.g., no fixed residence or overseas patients);\n* 13．Suspected vasculitis or septic embolism;\n* 14．Suspected aortic dissection;\n* 15．Evidence of intracranial tumor (except small meningioma), acute intracranial hemorrhage, tumor, or arteriovenous malformation;\n* 16．Significant mass effect with midline shift;\n* 17．Evidence of internal carotid artery dissection causing flow limitation;\n* 18．Neurological disease or psychiatric disorder that may interfere with evaluation of the patient's condition;\n* 19．Pregnant or breastfeeding women;\n* 20．Confirmed rheumatic or autoimmune disease with long-term use of immunosuppressants or corticosteroids;\n* 21．Current treatment with chemotherapy or other immunomodulatory agents (e.g., recombinant human granulocyte colony-stimulating factor, Xuebijing, or ulinastatin);\n* 22．Participation in another clinical trial that may interfere with the results of this study;\n* 23．Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation or may pose a significant risk to the patient.","ALL","18 Years","80 Years",{"count":20,"type":21},868,"ESTIMATED","INTERVENTIONAL",[24],"NA","Stroke remains a major global health burden, with acute ischemic stroke (AIS) accounting for more than 65% of all cases. Endovascular thrombectomy (EVT) has been established as a standard treatment for large vessel occlusion (LVO) stroke; however, \"futile recanalization\" remains common, with many patients failing to achieve favorable functional outcomes despite successful vessel reperfusion. Increasing evidence indicates that neutrophils and neutrophil extracellular traps (NETs) play important roles in post-reperfusion inflammation, thrombosis, and microcirculatory dysfunction, which may contribute to thrombolysis resistance and poor prognosis. Neutrophil elastase (NE), a key component associated with NETs, may further aggravate vascular injury and thrombus formation.\n\nSivelestat Sodium is a selective NE inhibitor that has demonstrated anti-inflammatory and organ-protective effects in patients with acute respiratory distress syndrome and in experimental models of cerebral ischemia. It may help preserve blood-brain barrier integrity, reduce brain edema, and improve neurological outcomes. Based on these findings, this study is designed as a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of sivelestat sodium as an adjunct to EVT in patients with acute anterior circulation large-vessel occlusive stroke within 24 hours of onset. The results of this study are expected to provide further clinical evidence for anti-inflammatory adjunctive treatment strategies aimed at reducing futile recanalization and improving functional outcomes in AIS.",[27,28,29,30],"Acute Ischemic Stroke","Large Vessel Occlusion","Thrombectomy","Neutrophil Extracellular Trap Formation",[32,33,34],"Endovascular Thrombectomy","Sivelestat Sodium","Neutrophil elastase","RECRUITING","2026-06-22",{"date":38,"type":39},"2026-06-25","ACTUAL",{"date":36,"type":39},{"date":42,"type":21},"2029-05-31",{"name":44,"class":45},"Xuanwu Hospital, Beijing","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100644479","phase-3-direct-angio-suite-acute-stroke-intervention-with-ctdsa-hybrid-emergency-stroke-unit-100644479","NCT07670065","Direct Angio Suite Acute Stroke Intervention With CT\u002FDSA Hybrid Emergency Stroke Unit","Direct Angio Suite Acute Stroke Intervention With CT\u002FDSA Hybrid Emergency Stroke Unit to Reduce Time to Endovascular Reperfusion for Acute Ischemic Stroke","Inclusion Criteria\n\n1. Age 18-60 years;\n2. Clinical diagnosis of acute ischemic stroke eligible for immediate endovascular treatment;\n3. Time from symptom onset or last known well ≤ 24 hours;\n4. Intravenous intracranial and cervical CT angiography completed;\n5. Confirmed target vessel occlusion amenable to endovascular intervention based on intravenous intracranial and cervical CT angiography findings;\n6. Written informed consent obtained from the patient or their legally authorized representative.\n\nExclusion Criteria\n\n1. Known contrast agent allergy;\n2. Renal insufficiency with GFR (glomerular filtration rate) \\\u003C 45 mL\u002Fmin\u002F1.73 m²;\n3. History of kidney transplantation;\n4. Concomitant diabetes mellitus with current use of metformin;\n5. Women who are pregnant, breastfeeding, or have a positive pregnancy test at admission;\n6. Refractory hypertension (defined as systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) (Note: patients may be enrolled if blood pressure is successfully reduced and maintained at an acceptable level with antihypertensive therapy);\n7. Intracranial space-occupying lesion or other conditions deemed unsuitable for endovascular intervention on imaging;\n8. Any other serious comorbidity or complication that may interfere with study conduct or evaluation.","60 Years",{"count":56,"type":21},232,[58],"PHASE3","This study investigates whether direct transfer to an emergency stroke unit equipped with NeuAngio-CT reduces time to endovascular reperfusion in patients with acute ischemic stroke and suspected intracranial large-vessel occlusion.Those aged 18-60 years with acute ischemic stroke who are eligible for endovascular thrombectomy within 24 hours of symptom onset will be enrolled. Participants will be randomly assigned to one of two groups. In the intervention group, participants will undergo femoral or radial artery puncture, followed by intracranial and cervical CT angiography with intra-arterial contrast injection (iacCTA) performed using the sliding-rail NeuAngio-CT, and subsequent thrombectomy guided by fused CTA-DSA images. In the control group, participants will receive intracranial and cervical CT angiography with intra-venous contrast injection and the thrombectomy will guided by standard DSA imaging without use of the sliding-rail CT. The primary endpoint is puncture-to-successful-reperfusion time (PRT); if successful reperfusion is not achieved, the end-of-procedure time will be used.",[27,28],[62,63,64,65],"Sliding CT\u002FDSA","One-stop Management","Mechanical Thrombectomy","Emergency Stroke Care","NOT_YET_RECRUITING","2026-06-21",{"date":69,"type":39},"2026-06-26",{"date":71,"type":21},"2026-06-08",{"date":73,"type":21},"2027-10-15",{"name":75,"class":45},"Beijing Tiantan Hospital",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100610730","a-comparison-of-cyclic-manual-direct-aspiration-thrombectomy-plunger-technique-vs-static-manual-direct-aspiration-thrombectomy-for-treatment-of-acute-large-vessel-occlusion-stroke-100610730","NCT07231380","A Comparison of Cyclic Manual Direct Aspiration Thrombectomy (Plunger Technique) vs. Static Manual Direct Aspiration Thrombectomy for Treatment of Acute Large Vessel Occlusion Stroke","Plunger Stroke Trial: A Comparison of Cyclic Manual Direct Aspiration Thrombectomy (Plunger Technique) vs. Static Manual Direct Aspiration Thrombectomy for Treatment of Acute Large Vessel Occlusion Stroke With the Raptor Aspiration Catheter","Plunger","Inclusion Criteria:\n\n\\- Acute ischemic stroke due to occlusion of the terminal ICA or M1 segment of the MCA, Treatment can be initiated within 24 hours of symptom onset, Age 18 years or older\n\nExclusion Criteria:\n\n* Evidence of acute intracranial hemorrhage prior to treatment, Failure to obtain informed consent",{"count":86,"type":21},500,[24],"This prospective, randomized controlled trial will compare two manual aspiration techniques for treating acute ischemic stroke due to large vessel occlusion: cyclic aspiration (Plunger technique) and static aspiration. Both techniques use FDA-approved devices (Raptor Aspiration Catheters and VacLok syringes) and are standard of care. Approximately 500 participants across 20 sites will be randomized to one of the two techniques. The primary endpoint is First Pass Effect (TICI 2c\u002F3 after first attempt), with secondary endpoints including overall recanalization and 90-day functional outcomes. Results will address a critical gap in optimizing aspiration thrombectomy techniques.",[90,28],"Acute Ischemic Stroke Patients",[27,28,92,93,94],"Mechanical Aspiration Thrombectomy","Plunger Technique","Stroke Intervention","2026-05-15",{"date":97,"type":39},"2026-05-19",{"date":99,"type":21},"2026-07-01",{"date":101,"type":21},"2027-06-01",{"name":103,"class":45},"Vanderbilt University Medical Center",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":76},"100634303","phase-3-intra-arterial-tirofiban-after-complete-recanalization-for-acute-intracranial-large-vessel-occlusion-100634303","NCT07537933","Intra-Arterial Tirofiban After Complete Recanalization for Acute Intracranial Large-Vessel Occlusion","Efficacy and Safety of Immediate Intra-Arterial Tirofiban After Mechanical Thrombectomy Recanalization in Acute Intracranial Large-Vessel Occlusion","IA-Tirofiban","Inclusion Criteria:\n\nAge ≥18 years; Last known well to arterial puncture within 0 to 24 hours; Preoperative imaging confirms anterior circulation large-vessel occlusion, including intracranial internal carotid artery occlusion or middle cerebral artery M1 or dominant M2 occlusion; Baseline National Institutes of Health Stroke Scale (NIHSS) score 6 to 25; Baseline Alberta Stroke Program Early CT Score (ASPECTS) ≥6 on CT or DWI; Pre-stroke modified Rankin Scale (mRS) score ≤1; eTICI 2c to 3 complete recanalization achieved after mechanical thrombectomy, or spontaneous recanalization to eTICI 2c to 3 confirmed intraoperatively without further thrombectomy; Embolic occlusion with no residual fixed stenosis in the target vessel after thrombectomy; Written informed consent provided by the participant or legally authorized representative.\n\nExclusion Criteria:\n\nPregnancy or breastfeeding; Active bleeding within the previous month or known severe bleeding tendency; Major underlying disease with life expectancy \\\u003C6 months, or inability in the investigator's judgment to complete follow-up; Participation in another interventional clinical trial; Use of oral anticoagulants within 48 hours before symptom onset with INR \\>1.7, or recent use of direct oral anticoagulants not meeting institutional cessation or testing requirements; Platelet count \\\u003C50 × 10\\^9\u002FL; Blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL that cannot be corrected promptly Severe renal insufficiency, defined as eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m² or serum creatinine \\>2.5 mg\u002FdL; Uncontrolled blood pressure, defined as systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg despite treatment; Imaging evidence of intracranial hemorrhage, or presence of an intracranial aneurysm, arteriovenous malformation, brain tumor, or other lesion associated with high bleeding risk; Bilateral acute cerebral infarction or multiple intracranial arterial occlusions Intraoperative vessel rupture, dissection, contrast extravasation, or other severe complications requiring a change in the standard anticoagulation strategy; Need for balloon angioplasty, permanent stent placement, or planned initiation of antiplatelet or anticoagulation therapy within 24 hours after the procedure; More than 3 thrombectomy passes or puncture-to-recanalization time \\>90 minutes; Use of an intraoperative intravenous heparin bolus, excluding heparinized saline flush; Suspected embolic stroke due to infection or infectious endocarditis; Severe allergy to contrast agents or tirofiban.",{"count":113,"type":21},344,[58],"The goal of this clinical trial is to learn if immediate intra-arterial tirofiban after complete recanalization can improve recovery in adults with acute ischemic stroke caused by anterior circulation large-vessel occlusion. It will also learn about the safety of this treatment. The main questions it aims to answer are:\n\nDoes immediate intra-arterial tirofiban after complete recanalization increase the number of participants with good functional outcome at 90 days? Does this treatment increase the risk of symptomatic intracranial hemorrhage or other important bleeding events?\n\nResearchers will compare immediate intra-arterial tirofiban with no intra-arterial tirofiban after complete recanalization to see if tirofiban improves recovery and is safe.\n\nParticipants will:\n\nBe enrolled after mechanical thrombectomy achieves complete recanalization Be randomly assigned to receive intra-arterial tirofiban or no intra-arterial tirofiban Receive follow-up assessments during hospitalization and at 90 days",[27,117,118],"Large-vessel Occlusion","Endovascular Treatment","2026-04-17",{"date":121,"type":39},"2026-04-22",{"date":123,"type":21},"2026-04",{"date":125,"type":21},"2028-04",{"name":127,"class":128},"Shandong Provincial Hospital","OTHER_GOV",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":148,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":76},"100633435","head-cooling-in-ischaemic-stroke-patients-undergoing-endovascular-thrombectomy-coolhead-2b-100633435","NCT07526649","Head Cooling in Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy (COOLHEAD-2b)","Head Cooling in Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy: A Phase 2 Randomised Controlled Trial (COOLHEAD-2b)","COOLHEAD-2B","Inclusion Criteria:\n\n* Acute anterior circulation ischaemic stroke planned for endovascular thrombectomy\n* Age ≥18 years\n\nExclusion Criteria:\n\n* Pre-stroke modified Rankin Scale score \\>2\n* Core body temperature \\\u003C35°C at admission\n* Uncontrolled hypertension (≥185\u002F110 mmHg despite treatment in IVT-eligible patients)\n* Known contraindications to hypothermia (e.g., haemodynamic instability, symptomatic bradyarrhythmia, cryoglobulinaemia, sickle cell disease, cold agglutinins)\n* Vasospastic disorders (e.g., Raynaud's phenomenon)\n* Skin lesions preventing secure application of the cooling cap\n* Inability to participate in 90-day follow-up",{"count":138,"type":21},182,[24],"COOLHEAD-2b is a multicentre, phase 2, prospective, randomised, controlled, open-label, blinded-endpoint trial evaluating the safety and efficacy of non-invasive convective head cooling as an adjunct to endovascular thrombectomy (EVT) in patients with acute anterior circulation ischaemic stroke. Head cooling is initiated as early as possible, including during inter-hospital transfer, and continued until one hour after reperfusion. The primary efficacy endpoint is final infarct volume at 24 hours.",[142,27,143,144,29,145,146,147,28],"Stroke","Brain Ischemia","Ischaemic Stroke","Endovascular Procedures","Reperfusion Injury","Cooling",[149,150,151,152,153,154],"Head cooling","Selective brain cooling","Endovascular thrombectomy","Therapeutic hypothermia","Penumbra","Neuroprotection","2026-04-09",{"date":157,"type":39},"2026-04-13",{"date":159,"type":21},"2026-04-10",{"date":161,"type":21},"2029-06-30",{"name":163,"class":128},"Auckland City Hospital",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":76},"100624070","non-invasive-vagus-nerve-stimulation-to-reduce-inflammation-and-brain-injury-blood-biomarkers-following-an-acute-ischemic-stroke-100624070","NCT07404852","Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemic Stroke","Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct 2","NUVISTA2","Inclusion Criteria:\n\n* Adult patients who present with acute ischemic strokes due to large vessel occlusions\n\nExclusion Criteria:\n\n* \\\u003C18 years old\n* patients with presumed chronic large vessel occlusions\n* NIHSS\\\u003C6\n* pre-morbid modified Rankin score (mRS) \\>2\n* unable to initiate treatment under 24 hours from symptom discovery\n* Chronic or acute infection, Recent surgery, active immune disease\n* life expectancy \\\u003C3 months\n* patients' undergoing active cancer or immunosuppressive\u002Fmodulating therapy\n* patients with sustained bradycardia on arrival with a heart rate \\\u003C50 beats per minute.","99 Years",{"count":174,"type":21},65,[24],"This is a randomized open-label, with blinded outcome pilot study to evaluate the effect on inflammatory and brain injury laboratory values and explore clinical outcomes in patients who present with ischemic strokes due to large vessel occlusions and are treated with either current accepted management, or accepted management in addition to transcutaneous auricular vagal nerve stimulation.",[28,27],[179,180,181,182,183],"Acute ischemic stroke","large vessel occlusion","cytokines","vagus nerve stimulator","brain injury biomarkers","2026-04-08",{"date":157,"type":39},{"date":187,"type":39},"2026-02-23",{"date":189,"type":21},"2028-02-29",{"name":191,"class":45},"Washington University School of Medicine",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":210,"leadSponsor":212,"locationsCount":76},"100632656","phase-2-intra-arterial-methylprednisolone-after-endovascular-thrombectomy-100632656","NCT07516522","Intra-arterial Methylprednisolone After Endovascular Thrombectomy","Intra-arterial Methylprednisolone After Successful Endovascular Thrombectomy Anterior Circulation Large Vessel Occlusion","IMPACT-LVO","Inclusion Criteria:\n\n* Age 18-80 years old;\n* The time from onset to randomization was within 24 hours;\n* Large vessel occlusive stroke in the anterior circulation confirmed by CTA\u002FMRA\u002FDSA (Including intracranial segment of internal carotid artery, M1 or M2 segment of middle cerebral artery) and the vessel responsible for the signs and symptoms of acute ischemic stroke;\n* NIHSS score \\>= 6 points\n* Alberta Stroke Program Early Diagnosis (ASPECTS) score of NCCT \\>=3;\n* Successful endovascular thrombectomy (eTICI 2b50-3)\n* Written informed consent signed by patients or their family members\n\nExclusion Criteria:\n\n* Intracranial hemorrhage confirmed by computed tomography (CT) or magnetic resonance imaging (MRI);\n* Prestroke mRS score \\>= 2\n* pregnant or lactating patients\n* Allergy to iodinated contrast media, or methylprednisolone sodium succinate\n* Participating in other clinical research;\n* Inherited\u002Facquired hemorrhagic diathesis (coagulation factor deficiency) or oral anticoagulation with international normalized ratio (INR) \\>1.7\n* History of major bleeding within the past 1 month (gastrointestinal\u002Fgenitourinary hemorrhage)\n* Chronic hemodialysis and severe renal insufficiency (glomerular filtration rate \\\u003C 30ml\u002Fmin\u002F1.73m\\^2 or serum creatinine \\> 220μmol\u002FL (2.5mg\u002Fdl));\n* Terminal illness with life expectancy \\\u003C6 months;\n* Blood glucose \\\u003C 2.8mmol\u002FL (50mg\u002Fdl) or \\> 22.2mmol\u002FL (400mg\u002Fdl);\n* Intracranial aneurysm, arteriovenous malformation, or space-occupying brain tumor with mass effect on imaging\n* Active systemic infectious disease\n* Anticipated inability to complete follow-up\n* Intraoperative DSA showed vascular perforation, dissection, and contrast extravasation;\n* Puncture to recanalization was more than 90 minutes;\n* Total thrombectomy passes \\>3",{"count":201,"type":21},210,[203],"PHASE2","The purpose of IMPACT-LVO trial is to investigate the efficacy and safety of early adjunctive intra-arterial combined with intravenous administration methylprednisolone sodium succinate after successful endovascular thrombectomy in anterior circulation large vessel occlusion patients.\n\nThis is a multicenter, randomized, double-blind, placebo-controlled trial. Acute ischemia stroke patients with anterior circulation large vessel occlusion within 24 hours from last known well will be screened for this trial. Successful recanalization after mechanical thrombectomy (eTICI 2b-3) patients will be randomized 1:1 to either methylprednisolone sodium succinate group or placebo group. The methylprednisolone sodium succinate group patients will receive intra-arterial methylprednisolone sodium succinate 40mg immediately after the recanalization. Then, intravenous administration with methylprednisolone sodium succinate 2mg\u002Fkg in the next 3 days. The placebo group patients will receive intra-arterial and intravenous sterile water for injection.\n\nThe shift on modified Rankin Scale score is designed to detect in the present trial. A sample size of n = 178 patients (n=89 per group) is required. The intention-to-treat principle will be applied to the primary analysis, therefore, to safeguard against dilution of the treatment effect associated with an approximate 15% non-adherence rate (due to loss to follow-up, consent withdrawal and other reasons), we planned to enrol n=210 patients (n=105 per group) for this study. The findings of IMPACT-LVO are likely to have a direct impact on clinical practice.",[206,29,28],"Ischemia Stroke","2026-03-31",{"date":184,"type":39},{"date":207,"type":39},{"date":211,"type":21},"2027-12-31",{"name":213,"class":45},"Tang-Du Hospital",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":46},"100612407","phase-3-tenecteplase-before-interhospital-transfer-for-evt-in-acute-anterior-circulation-lvo-at-45-24-hours-100612407","NCT07253181","Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours","Tenecteplase Before inteRhospital Transfer for Endovascular Treatment in pAtientS With acUte Anterior ciRculation Large vEssel Occlusion at 4.5 to 24 Hours","TREASURE","Inclusion Criteria:\n\n* Age of 18 years or older;\n* AIS symptom onset to treatment initiation within 4.5 to 24 hours, stroke onset is defined as the time the patient was last known to be well (including wake-up stroke and unwitnessed stroke);\n* Signs and symptoms consistent with the diagnosis of an acute anterior circulation ischemic stroke involving occlusion of the internal carotid artery (ICA), MCA (M1 or M2) vessels;\n* Functionally independent (mRS 0-2) prior to stroke onset;\n* Baseline National Institute of Health Stroke Scale (NIHSS) of 6-25;\n* Intended to transfer to ECCs for EVT (patient transfer), or intended to transfer a neurointerventionalist from the ECC for EVT (physician transfer);\n* Written informed consent from patients or legally authorized representatives;\n* Neuroimaging: ICA or M1, M2 occlusion by MRA or CTA AND the target mismatch profile on computed tomography perfusion (CTP) or magnetic resonance perfusion (MRP), defined as an ischemic core volume \\\u003C70mL, mismatch volume ≥15mL and mismatch ratio ≥1.8;\n\nAlternative neuroimaging (if CTP or MRP is technically inadequate or unavailable):\n\nThe presence of a diffusion-weighted imaging (DWI)-fluid-attenuated inversion recovery (FLAIR) mismatch pattern (i.e., acute ischemic lesion visible on DWI but no marked parenchymal hyperintensity visible on FLAIR) OR an Alberta Stroke Program Early CT Score (ASPECTS) score ≥7 on NCCT or MRI scan;\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to any ingredients of Tenecteplase;\n* Intended to receive IVT as standard-of-care therapy;\n* Rapidly improving symptoms with NIHSS score \\\u003C6 before randomization;\n* Any contra-indication for IVT except for the time criterion;\n* Known hereditary or acquired hemorrhagic diathesis;\n* Impairment in coagulation due to comorbid disease or anticoagulant use. If on warfarin, INR \\>1.7 or prothrombin time \\>15s; if use of any direct oral anticoagulant within the last 48 hours; if on any full dose heparin\u002Fheparinoid within the last 24 hours;\n* Ischemic stroke or myocardial infarction in previous 3 months\n* Previous intracranial hemorrhage, active internal bleeding (gastrointestinal or urinary tract hemorrhage) in previous 3 months;\n* Severe, uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg);\n* Other serious, advanced or terminal illness with life expectancy less than 6 months;\n* Baseline blood glucose \\\u003C50mg\u002Fdl or \\>400mg\u002Fdl;\n* Contraindication to imaging with contrast agents;\n* Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA or MRA (e.g. bilateral MCA occlusions, or an MCA and a basilar artery occlusion);\n* Extensive early ischemic change on non-contrast CT or MRI-DWI estimated to be \\>1\u002F3 MCA territory, or significant hypodensity outside the Tmax\\>6s perfusion lesion that invalidates mismatch criteria (if patient is enrolled based on CT perfusion criteria);\n* Evidence of intracranial tumor (mass effect), acute intracranial hemorrhage, or arteriovenous malformation;\n* Current participation in another investigational drug or device study;\n* Suspected endocarditis;\n* Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;",{"count":223,"type":21},572,[58],"This study will address the efficacy and safety of Tenecteplase administered in non-endovascular capable center (nECC) in patients with acute ischemic stroke (AIS) caused by anterior circulation large vessel occlusion (acLVO) who present in the 4.5- to 24-hour time window before interhospital transfer to an endovascular capable center (ECC) for endovascular treatment (EVT).\n\n* Primary objective: To evaluate the efficacy and safety of Tenecteplase administration at a nECC before EVT transfer compared with standard of care\n* Secondary objective: To evaluate the impact of time from needle-to-arterial puncture on clinical outcomes Patients who meet inclusion criteria will be randomized to Tenecteplase (0.25mg\u002Fkg, maximum 25mg) before transfer or standard of care. A single bolus dose should be injected over 5 seconds.",[27,28,227],"Transportation of Patients",[229,230,231],"interhospital transfer","acute ischemic stroke","anterior circulation large vessel occlusion","2026-03-16",{"date":234,"type":39},"2026-03-19",{"date":236,"type":39},"2026-01-06",{"date":238,"type":21},"2028-03-30",{"name":44,"class":45},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":247,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":76},"100629438","evaluation-of-a-point-of-care-lateral-flow-assay-in-glial-fibrillary-acidic-protein-gfap-and-d-dimer-in-diagnosis-of-large-vessel-occlusion-acute-ischemic-stroke-in-a-pediatric-hospital-100629438","NCT07474675","Evaluation of a Point-of-care Lateral Flow Assay in Glial Fibrillary Acidic Protein (GFAP) and D-dimer in Diagnosis of Large Vessel Occlusion Acute Ischemic Stroke in a Pediatric Hospital","Evaluation of a Point-of-care Lateral Flow Assay in GFAP and D-dimer in Diagnosis of Large Vessel Occlusion Acute Ischemic Stroke in a Pediatric Hospital","Inclusion Criteria:\n\n* Presenting with acute onset (\\\u003C18 hours) spontaneous (no trauma) focal neurologic deficit or altered consciousness\n\nExclusion Criteria:\n\n* Participants with surgery in the past month\n* Participants with known trauma in the past month\n* Participants with known seizure history or anti-seizure medications\n* Participants who are adults with decisional impairment","0 Years","21 Years",{"count":250,"type":21},250,"OBSERVATIONAL","The goal of this study is to test the efficacy of a rapid bedside blood test in determining if a stroke is happening in children who present to the emergency department with stroke symptoms. The main questions it aims to answer are:\n\n* To determine the sensitivity of detecting a large vessel occlusion (LVO) as the etiology of acute ischemic stroke (AIS) in a pediatric population using a point-of-care blood-based assay (LVOne).\n* To determine the positive predictive value (PPV) of LVOne in a pediatric population\n\nParticipants will:\n\n* Provide a small sample of blood to be used to test the accuracy of the device.\n* Participants will still receive all standard of care work-up for stroke, which could include computed tomography\u002Fmagnetic resonance imaging (CT\u002FMRI).",[254,28,27],"Stroke Code",[142],"2026-03-12",{"date":232,"type":39},{"date":259,"type":21},"2026-03",{"date":261,"type":21},"2028-07",{"name":263,"class":45},"Boston Children's Hospital",{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":285,"leadSponsor":287,"locationsCount":76},"100628367","advancing-reperfusion-therapy-for-ischemic-stroke-direct-transfer-to-angiography-suite-for-patients-with-suspected-large-vessel-occlusion-100628367","NCT07460713","Advancing Reperfusion Therapy for Ischemic Stroke: Direct Transfer to Angiography Suite for Patients With Suspected Large Vessel Occlusion","Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Direct Transfer to Angiography Suite (DTAS) for Patients With Suspected Large Vessel Occlusion","ARTS-DTAS","Inclusion Criteria:\n\n* Age≥18 years old;\n* Patients presenting with symptoms or signs suggestive of acute large vessel occlusion (LVO) stroke；\n* Randomization within 6 hours of symptom onset；\n* Baseline NIHSS score ≥10 points prior to randomization;\n* Pre-stroke modified Rankin Scale (mRS) score ≤2;\n* Written informed consent from patients or their legally authorized representatives.\n\nExclusion Criteria:\n\n* Refusal of endovascular treatment；\n* Allergy to contrast agents;\n* Clinical symptoms or signs suggestive of intracranial hemorrhage (e.g., severe headache, seizures, or signs of increased intracranial pressure);\n* Transferred patients (e.g., from centers without thrombectomy capability);\n* Seizure at stroke onset, postictal paralysis, or inability or unwillingness to cooperate due to epilepsy or other neurological or psychiatric disorders;\n* Clinically unstable conditions requiring urgent life-support treatment;\n* Other standard contraindications to endovascular treatment;\n* Any terminal illness such that the patient would not be expected to survive more than 1 year;\n* Pregnant women, nursing mothers, or women with a positive pregnancy test at admission;\n* Unlikely to adhere to the trial protocol or follow-up;\n* Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;\n* Participation in other interventional clinical trials within the previous 3 months.",{"count":273,"type":21},568,[24],"The investigators initiated a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled trial to evaluate the efficacy and safety of the direct transfer to angiography suite (DTAS) triage strategy compared to the conventional triage strategy with CT\u002FMRI in patients with suspected large artery occlusive (LVO) within 6 hours of symptom onset.",[277,28],"Ischemic Stroke",[279,180,280,281],"ischemic stroke","endovascular treatment","direct transfer to angiography suite","2026-03-10",{"date":256,"type":39},{"date":207,"type":21},{"date":286,"type":21},"2028-09-30",{"name":75,"class":45},{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":310,"leadSponsor":312,"locationsCount":76},"100621208","head-of-bed-after-ischemic-stroke-thrombectomy-hobit-100621208","NCT07367633","Head of Bed After Ischemic Stroke Thrombectomy (HoBIT)","A Pragmatic, Multicentre, Adaptive, Prospective, Open-label, Blinded Endpoint Randomized Clinical Trial Assessing the Impact of Head-of-bed Positioning at 0-degrees Versus 30-degrees or More on Functional Recovery Following Endovascular Thrombectomy for Anterior Circulation Large Vessel Occlusion Stroke.","HoBIT","Inclusion Criteria:\n\n* Age 18 years or older on the date of randomization\n* Endovascular thrombectomy (EVT) for large vessel occlusion (LVO) in the anterior circulation, according to current guidelines and local standards of clinical care. The definition of LVO may include the intracranial segment of the internal carotid artery (ICA), and\u002F or the M1 segment (proximal, mid, distal) of the middle cerebral artery (M1-MCA), and\u002F or the proximal M2 segment of the MCA (M2-MCA)\n* Capable of giving signed informed consent either independently, or by a legally authorized representative (LAR), or via a deferred consent process approved by the relevant ethics committee, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\nExclusion Criteria:\n\n* Mechanical ventilatory support for acute medical condition prior to procedure (i.e. required for reasons other than procedure)\n* Symptomatic congestive heart failure, chronic obstructive pulmonary disease, or any other medical condition that would make either HoB position inappropriate for patient care in the judgement of the investigator.\n* Any condition, such as but not limited to, agitation\u002F delirium or severe nausea\u002F vomiting, that, in the view of the investigator, is expected to significantly impede maintaining the assigned HoB\n* Any condition with life expectancy of less than 3 months\n* Inability to randomize within 1 hour from the end of the EVT",{"count":297,"type":21},2240,[24],"Endovascular thrombectomy (EVT), also known as clot retrieval, is a procedure that improves recovery for people who suffer a stroke by removing blood clots from large blood vessels in the brain. However, half of the patients undergoing EVT to remove the clot from a brain vessel still face lasting disabilities or even die within three months.\n\nThe investigators of the HoBIT trial are trying to find out if the position of the head of bed improves recovery in patients who undergo EVT after suffering from a stroke.\n\nThe purpose of this study is to establish the benefit of head of bed positioning at 0-degrees compared with 30-degrees or more after EVT for improving functional outcomes in adults that suffer from a stroke.",[28,142,277],[302,303,180,304,305],"head of bed","stroke","endovascular thrombectomy","EVT","2026-02-03",{"date":308,"type":39},"2026-02-05",{"date":259,"type":21},{"date":311,"type":21},"2028-12",{"name":313,"class":45},"Population Health Research Institute",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":328,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":46},"100606357","evaluation-of-the-conda-stent-retriever-in-acute-ischemic-stroke-100606357","NCT07174505","Evaluation of the CONDA Stent Retriever in Acute Ischemic Stroke","A Prospective, Single-Arm, Multi-Center Study to Assess the Safety, Performance, and Preliminary Efficacy of Mechanical Thrombectomy Using the CONDA Stent Retriever in Subjects With Acute Ischemic Stroke","ARTEMIS","Inclusion Criteria:\n\n1. Age 18 to 85 years.\n2. Informed consent was obtained from subject or acceptable subject surrogate (e.g., next of kin, or legal representative).\n3. New focal disabling neurologic deficit consistent with acute cerebral ischemia.\n4. Baseline NIHSS obtained prior to procedure ≥ 6 points and ≤ 25 points.\n5. Pre-ictal mRS score of 0, 1 or 2.\n6. Treatable within 24 hours of stroke symptom onset.\n7. If indicated, thrombolytic therapy shall be initiated following recommendations established by the AHA\u002FASA and\u002For ESO Guidelines. Subjects eligible for IV thrombolysis should receive it without delay.\n8. Extended Thrombolysis in Cerebral Infarction (eTICI) Score 0 - 1, confirmed by angiography or CTA\u002FMRA of the:\n\n   1. Intracranial internal carotid artery (ICA)\n   2. Middle cerebral artery - M1 segment\n   3. Middle cerebral artery - M2 proximal or dominant segments\n9. Imaging criteria:\n\n   * Alberta Stroke Program Early CT Score (ASPECTS) 6 to 10 on baseline CT or DWI-MRI.\n   * If automated assessment, core volume of ≤50 cc on CTP\u002F DWI-MRI.\n\nExclusion Criteria:\n\nThe following exclusion criteria will be assessed pre-operatively:\n\n1. Rapid neurological improvement prior to enrollment suggesting resolution of stroke.\n2. Subject was diagnosed with a stroke in the last 6 months.\n3. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.\n4. Clinical presentation suggests subarachnoid hemorrhage.\n5. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with antivitamin K, with INR \\>3.0.\n6. Known baseline glucose of \\\u003C50 mg\u002FdL or \\>400 mg\u002FdL.\n7. Severe, sustained uncontrolled hypertension refractory to treatment (systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg).\n8. Serious, advanced, or terminal disease with anticipated life expectancy of less than 1 year.\n9. Known history of severe sensitivity (more than rash) to contrast medium.\n10. Known history of severe sensitivity to nickel, titanium metals or their alloys.\n11. Known renal insufficiency with creatinine ≥3 mg\u002FdL or glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin.\n12. Subject requires hemodialysis or peritoneal dialysis.\n13. Subject is a current user or has a recent history of cocaine and\u002For heroin use.\n14. Known pregnancy and\u002For lactating female.\n15. Subject is participating in a concurrent study involving an investigational drug or device that would impact the primary endpoint of this study.\n16. Subject is unlikely to be available for a 90-day follow-up (e.g., no fixed home address, visitor from overseas, etc.)\n17. CT or MRI evidence of hemorrhage (the presence of microbleeds is allowed).\n18. CT or MRI evidence of significant mass effect with midline shift.\n19. CT or MRI evidence of intracranial tumor (except asymptomatic meningioma of ≤ 2cm in diameter).\n20. CT or MR evidence of cerebral vasculitis.\n21. Suspicion of aortic dissection, presumed septic embolus, or bacterial endocarditis.\n22. History of preexisting stent proximal to or at the occlusion site that may preclude safe deployment or recovery of the stent retriever.\n\n    The following exclusion criteria will be assessed intra-operatively:\n23. eTICI score improvement to greater than eTICI 1 after initial screening and prior to intervention.\n24. Initially treated with a different thrombectomy device during the current study procedure.\n25. Vessel tortuosity too difficult to allow endovascular access of the intracranial internal carotid artery (ICA) per investigator judgement. Indicators of vessel tortuosity include but are not limited to the presence of carotid loops and type 3 aortic arches.\n26. Evidence of tandem lesions, including complete occlusion, high-grade stenosis or arterial dissection in the extracranial or intracranial internal carotid artery (ICA), requiring treatment or preventing access to thrombus.\n27. Underlying intracranial atherosclerotic disease (ICAD) lesions responsible for the target occlusion.\n28. Occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior\u002Fposterior circulation).\n29. Inability to gain arterial access.","85 Years",{"count":324,"type":21},50,[24],"The goal of this study is to evaluate the safety and performance of the CONDA stent retriever in patients with acute ischemic stroke due to large vessel occlusion, treated within 24 hours of symptom onset.\n\nThe main objectives are:\n\n* To determine the rate of device success, defined as the ability of the CONDA retriever to reach the blocked vessel, be deployed and retrieved successfully, and facilitate reperfusion.\n* To evaluate safety, measured as the rate of symptomatic intracranial hemorrhage within 24 hours of the procedure.\n\nThe use of CONDA in this study follows the same approach as other CE-marked stent retrievers. Supportive devices (such as long sheaths, guide catheters, balloon catheters, distal access catheters, the ANA funnel catheter, microcatheters, and microwires) may be used according to investigator preference and local practice, in line with their labeling and instructions for use.\n\nParticipants will:\n\n* Be evaluated using standard clinical and imaging assessments to confirm eligibility.\n* Undergo mechanical thrombectomy with the CONDA device, with or without supportive devices as selected by the treating physician.\n* Have standard follow-up evaluations to assess treatment safety and effectiveness.",[27,28],[329,330,331],"Acute Ischemic Stroke (AIS)","mechanical thrombectomy","stent retriever","2025-09-11",{"date":334,"type":39},"2025-09-16",{"date":336,"type":21},"2025-10-01",{"date":338,"type":21},"2027-01-01",{"name":340,"class":341},"Anaconda Biomed S.L.","INDUSTRY",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":76},"100605880","phase-3-tenecteplase-vs-medical-management-in-45-24h-lvo-no-access-to-evt-100605880","NCT07168278","Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT","Tenecteplase vs Medical Management in 4.5-24h Anterior Circulation Large Vessel Occlusion With no Access to EVT","TNK LATE","Inclusion Criteria:\n\n* Age 18 years or greater\n* Acute ischemic stroke presenting in the 4.5 to 24 hour window from last seen well (including wake-up stroke and no witness stroke).\n* Prestroke mRS 0-2\n* NIHSS 6 to 25\n* Aspect ≥ 7\n* ICA terminus, M1, dominant M2 occlusion on CTA or MRA\n* Clinical-imaging mismatch assessed by investigator\n* Patients with no access to EVT at the time of randomization\n\nExclusion Criteria:\n\n* Current or past history of significant bleeding over the past 6 months;\n* History of intracranial hemorrhage (including possible subarachnoid hemorrhage or subarachnoid hemorrhage due to an aneurysm) or evidence or suspected intracranial hemorrhage;\n* Known bleeding tendency;\n* Recent severe or dangerous bleeding, or active ulcerative gastrointestinal disease;\n* History of central nervous system injury (e.g., intracranial tumor, aneurysm, or arteriovenous malformation, intracranial or spinal surgery), or recent head injury；\n* Tumors that increase risk of bleeding;\n* Severe liver dysfunction, including liver failure, cirrhosis, portal hypertension (esophageal varices), and active hepatitis;\n* Know arterial \u002F venous malformation or aneurysm;\n* Bacterial endocarditis, pericarditis, or acute pancreatitis;\n* Patients receiving effective anticoagulant therapy (vitamin K antagonists with INR \\> 1.3, or other oral anticoagulants exceeding the upper limit of the corresponding standard range);\n* Heparin use within the past 48 hours and prothrombin time exceeding the upper limit of the standard range;\n* Over the past 3 months, undergone major surgery, organ biopsy, or suffered a serious injury;\n* Over the past 2 weeks, receiving prolonged ( \\>2 minutes) cardiopulmonary resuscitation, childbirth, or non-stressful vascular puncture (such as subclavian or jugular vein puncture);\n* Stroke episode occurred with epileptic seizure;\n* History of stroke comorbid with diabetes;\n* History of stroke over the past 3 months；\n* Acute bleeding tendency, including platelet count below 100×10⁹\u002FL or other conditions;\n* SBP \\>185 mmHg or DBP \\>110 mmHg, or requiring intensive treatment (intravenous antihypertensive drugs) to lower blood pressure to within limits;\n* Blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL (\\\u003C50 mg\u002FdL or \\>400 mg\u002FdL)；\n* Patient life expectancy of less than 1 year;\n* Simultaneous occlusion of multiple blood vessels, defined as bilateral MCAs or MCAs combined with the basilar artery;\n* Pregnant women or nursing mothers；\n* Patients with a low likelihood of 3-month follow-up；\n* Over the past 3 months participated in other interventional clinical trials.",{"count":351,"type":21},794,[58],"The goal of this clinical trial is to learn if tenectplase works to acute ischemic stroke (AIS) with onset 4.5-9 hours. It will also learn about the safety of tenectplase in AIS with onset 4.5-9 hours. The main question it aims to answer is: Does tenectplase improve the 90-days functional outcome in participants with acute large vessel occlusion? Researchers will compare tenectplase thrombolysis to non-use to see if tenectplase works to improve the functional outcome in participants with onset 4.5-9 hours. Participants will:\\* Receive 0.25mg\u002Fkg (max 25mg) tenectplase at admission (after randomization) .\\* Receive neurological assessment at admission, Day 5-7 or on hospital discharge (whichever earlier). Audio or video of the assessment may be recorded if possible.\\* Receive brain CT + CT angiogram + CT perfusion and MRI after randomization, where the CT scan may be repetitive.",[27,28,355,356],"Tenecteplase","Thrombolysis","2025-09-05",{"date":332,"type":39},{"date":360,"type":21},"2025-11-01",{"date":362,"type":21},"2028-05-31",{"name":364,"class":45},"The First Affiliated Hospital of University of Science and Technology of China",{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":374,"conditions":375,"keywords":377,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":76},"100600600","image-detection-of-impaired-microcirculatory-reperfusion-100600600","NCT07099599","Image Detection of Impaired Microcirculatory Reperfusion","ID IMR","Inclusion Criteria:\n\n* Adults greater than or equal to 18 years of age\n* Last known normal (LKN) within 24 hours\n* Ischemic stroke due to anterior circulation LVO (intracranial internal carotid artery \\[ICA\\], proximal middle cerebral artery \\[M1\\], M1\u002FM2 bifurcation, or proximal dominant M2 occlusion)\n* mTICI2c or mTICI3 on digital subtracted angiography (DSA) following mechanical thrombectomy\n\nExclusion Criteria:\n\n* Significant renal insufficiency (glomerular filtration rate \\<30mg\u002Fml\u002Fmin2 while not on dialysis)\n* Contraindication to iodinated contrast\n* Contraindication to magnetic resonance imaging (e.g., pacemaker incompatibility)\n* Prior significant stroke in same vascular territory ipsilateral stroke\n* Tandem vessel occlusion (i.e., extracranial ICA and ipsilateral intracranial M1\u002FM2 occlusion)\n* Greater than 4 clot retrieval attempts\n* Enrollment in another acute stroke interventional study (with the exception of thrombectomy device registries)\n* Pregnancy\n* Prisoners",{"count":373,"type":21},40,"Stroke affects one patient every 40 seconds in the United States. It is most commonly caused by blood clots that develop in the blood vessels of the brain. These blood clots interrupt the normal flow of blood and oxygen to the nerve cells in the brain. When this occurs, the nerve cells can die, causing permanent damage to that area of the brain. That damage can result in loss of normal function to a patient's vision, strength, sensation, balance, or speech. These changes can remain permanent if blood flow is not restored to the brain. Thankfully, there are treatments available to help get rid of these blood clots. One of these treatments is a procedure to physically remove the blood clot causing stroke. This practice is now routinely done at all major stroke centers.\n\nSpecial imaging for stroke is now available at these major stroke centers. This imaging looks at blood flow in and around the area of brain that is dying. By performing these scans after the procedure, we can see that not all of brain is being saved by the procedure. That is a problem, because we know that saving brain cells can make a big difference in how patients recover from stroke. The purpose of this study is to determine which brain tissue will not get saved by blood clot removal. We will do this by using specialized imaging after the procedure. The study will discover if there is more brain tissue that can be saved after the procedure. Once we can determine this, our next steps will be looking at ways to save this tissue in the studies that follow. For example, we will look to see if medications can be given after the procedure to help save those brain areas. This study lays the groundwork for future studies to help save all the brain tissue we possibly can from dying during the stroke. This is our best chance of getting all patients affected by stroke the opportunity to live their best lives after stroke.",[376,28],"Ischemic Stroke, Acute",[378,379,277],"No Reflow","Microcirculatory Reperfusion","2025-07-25",{"date":382,"type":39},"2025-08-01",{"date":384,"type":39},"2024-09-30",{"date":386,"type":21},"2027-03-31",{"name":388,"class":45},"University of Cincinnati",{"id":390,"slug":391,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":397,"conditions":398,"keywords":399,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":408,"locationsCount":410},"100590136","cerebral-large-vessel-occlusion-stroke-multiomics-biosample-cohort-100590136","NCT06963489","Cerebral Large Vessel Occlusion Stroke Multiomics Biosample Cohort","CLOMB","Inclusion Criteria:\n\n1. Age over 18 years.\n2. Patients with intracranial and extracranial large vessel occlusion ischemic stroke confirmed by cerebrovascular angiography.\n3. Availability of complete clinical and follow-up information required for the study.\n4. Availability of blood and\u002For thrombus biological samples.\n5. Voluntary written informed consent signed by the patient or their family (1) For retrospectively enrolled patients, a \"broad informed consent\" was signed at the time of sample collection. Upon enrollment into the cohort, a follow-up phone call was made to confirm the informed consent.\n\n(2) For prospectively enrolled patients, informed consent for this study was signed at the time of enrollment by the patient or their family.\n\nExclusion Criteria:\n\n1. Patients for whom biological samples cannot be obtained;\n2. Patients or their family members who refuse to sign the informed consent form.",{"count":86,"type":21},"This multicenter, ambispective cohort study establishes a comprehensive multiomics biobank from five stroke centers, encompassing thrombi, intracranial blood, peripheral arterial\u002Fvenous blood, and clinical-laboratory-imaging-follow-up data from patients with acute ischemic stroke with large vessel occlusion (AIS-LVO).",[28,27],[400,401],"multiomics","acute ischemic stroke with large vessel occlusion","2025-05-09",{"date":404,"type":39},"2025-05-11",{"date":406,"type":39},"2025-04-27",{"date":189,"type":21},{"name":409,"class":45},"First Affiliated Hospital of Wannan Medical College",5,{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":418,"targetDuration":420,"studyType":251,"phases":4,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":76},"100505688","acute-ischemic-stroke-endovascular-therapy-a-multicenter-registry-study-100505688","NCT05864638","Acute Ischemic Stroke EndoVascular Therapy: a Multicenter REGISTRY Study","Acute Ischemic Stroke EndoVascular Therapy: a Multicenter REGISTRY Study （OCIN-AIS-EVT REGISTRY）","Inclusion Criteria:\n\n1. Acute ischemic stroke caused by anterior or posterior circulation vessel occlusion confirmed by computed tomography angiography (CTA) or magnetic resonance angiography (MRA) or digital subtraction angiography (DSA)\n2. Undergo intravascular therapy (i.e. access to a cath lab and an arterial puncture)\n3. The patient or his\u002Fher legal representative agreed to participate in the study and has signed the informed consent.\n\nExclusion Criteria:\n\n1\\) No exclusion criteria",{"count":419,"type":21},10000,"90 Days","A Multicenter Registry of Endovascular Treatment for Acute Ischemic Stroke.",[27,28,29,423],"Thrombosis","2025-01-23",{"date":426,"type":39},"2025-01-27",{"date":428,"type":39},"2023-05-10",{"date":430,"type":21},"2028-08-31",{"name":432,"class":45},"Changhai Hospital",{"id":434,"slug":435,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":76},"100576694","phase-3-glucagon-like-peptide-1-receptor-agonist-in-acute-large-vessel-occlusion-stroke-after-endovascular-treatment-100576694","NCT06788626","Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment","GALLOP2","Inclusion Criteria:\n\n1. LVO stroke at terminal ICA, M1 or dominant M2 with an LKW-to-randomization ≤24 hours\n2. Age ≥ 18 years old\n3. National Institute of Health Stroke Scale ≥ 6 at the time of brain imaging\n4. Acute LVO stroke due to thromboembolism or intracranial stenosis\n5. Patients who received computer tomographic or magnetic resonance angiography\n6. ASPECTS ≥ 6 for patients with LKW-to-randomization ≤6 hours\n7. Salvageable ischemic penumbra demonstrated by CT perfusion or MRI for patients with LKW-to-randomization between 6 and 24 hours\n8. Informed consent obtained from patient or acceptable patient surrogate.\n\nExclusion Criteria:\n\n1. Use of intravenous thrombolytic therapy (alteplase or tenecteplase)\n2. Pre-stroke mRS \\> 2 for patients \\\u003C80 years and \\> 1 for patients ≥ 80 years old\n3. Intracranial hemorrhage or brain tumour on initial imaging (except small meningiomas)\n4. Simultaneous occlusion of bilateral anterior circulation, or both anterior and posterior circulation\n5. Unstable hemodynamics on presentation that require resuscitation\n6. Systolic blood pressure \\>185mmHg or diastolic blood pressure \\>110mmHg that cannot be controlled by antihypertensive drugs\n7. Severe comorbid illness, e.g. terminal malignancy with life expectancy \\\u003C1 year\n8. Pregnant or lactating female\n9. Participation in another clinical trial\n10. Contraindications to GLP1-RA, including history of allergy to GLP-1RA, family or personal history of multiple endocrine neoplasia, medullary thyroid or pancreatic carcinoma, or proliferative diabetic retinopathy\n11. Blood glucose \\\u003C2.7 or \\> 22.2 mmol\u002FL; platelet count \\\u003C50x10\\^9 \u002FL; INR \\>1.7\n12. Patients with known estimated glomerular filtration rate of \\\u003C30ml\u002Fmin\u002F1.73m2 or creatinine \\>3mg\u002FdL (265.2µmol\u002FL); chronic liver disease with Child's Pugh score C or above; or recurrent unexplained hypoglycemia.\n13. Suspected or confirmed vasculitis of the central nervous system\n14. Unable to complete 90-day follow-up assessment",{"count":441,"type":21},390,[58],"The goal of this clinical trial is to learn if semaglutide works to treat acute ischemic stroke (AIS). It will also learn about the safety of semaglutide in AIS. The main question it aims to answer is: Does semaglutide improve the 90-days functional outcome in participants with acute large vessel occlusion who receive the endovascular treatment (EVT)? Researchers will compare semaglutide injection to non-injection to see if semaglutide works to improve the functional outcome in participants with EVT.\n\nParticipants will:\n\n* Receive 0.5mg semaglutide injection before (Day 0) and 1 week (Day 7) after EVT , or EVT alone.\n* Have additional blood test before and after EVT.\n* Receive neurological assessment before EVT, Day 1, Day 3, Day 5-7 after EVT or on hospital discharge (whichever earlier), Day 90±14 after EVT. Audio or video of the assessment may be recorded if possible.\n* Receive brain CT + CT angiogram + CT perfusion and MRI after EVT, where the CT scan may be repetitive.",[27,28,445,118],"Neuroprotective Drugs","2025-01-21",{"date":424,"type":39},{"date":449,"type":21},"2025-02",{"date":451,"type":21},"2028-02",{"name":453,"class":45},"Wei Hu",{"id":455,"slug":456,"hasResults":11,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":22,"phases":464,"briefSummary":465,"conditions":466,"keywords":467,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":76},"100539251","phase-3-combination-of-hypothermia-and-thrombectomy-in-acute-stroke-100539251","NCT06301412","Combination of Hypothermia and Thrombectomy in Acute Stroke","Combination of Targeted Temperature Management and Thrombectomy After Acute Ischemic Stroke (COTTIS-2) - a Randomised Controlled Study","COTTIS-2","Inclusion Criteria:\n\n* Pre-stroke modified Rankin Scale (mRS) 0-2 \\[7-point scale rating from 0 (no symptoms) to 6 (dead)\\]\n* Acute ischemic stroke with NIHSS \\>5\n* Intracranial occlusion of the M1 or M2 segment of the middle cerebral artery (MCA) or internal carotid artery (ICA) or tandem occlusion on CT-angiography or MR-angiography with indication for endovascular treatment:\n* Time window 0-24h:\n\n  1. Last seen normal to groin puncture \\\u003C 6h: native CT or MRI-DWI with ASPECTS \\>5\n  2. Last seen normal to groin puncture 6-24h or unknown time window: significant mismatch imaging according to the eligibility criteria of the DEFUSE-3 trial\n\n     * Infarct core \\\u003C70ml (DWI oder CBF\\\u003C30%)\n     * Penumbra \\> 15ml (Tmax \\>6sec)\n     * Ratio penumbra\u002Fcore \\>1.8\n* with or without iv thrombolysis with rtPA\n\nExclusion Criteria:\n\n* Patients with an intranasal obstruction that prevents complete insertion of the nasal cannula should not be treated with the RhinoChill system.\n* Known severe hemorrhagic diathesis (International Normalized Ratio (INR) \\>3.0, partial thromboplastin time (PTT) \\> 70s, platelet count \\\u003C 50.000\u002Fμl)\n* Brain trauma or neurovascular surgery\u002Fintervention \\\u003C3 months\n* Severe infection\n* Pregnant women or women of childbearing potential (women of childbearing potential with negative pregnancy test may be included)\n* Known cerebral vasculitis\n* Proof of bleeding in cerebral CT or MRI (cerebral microbleeds in MRI \\[hypertensive or in the context of cerebral amyloid angiopathy\\] is permitted).\n* Known life expectancy \\\u003C 6 months",{"count":463,"type":21},400,[58],"The goal of this clinical trial is to test the combination of hypothermia and endovascular treatment in acute stroke patients with large vessel occlusion.\n\nThe main question it aims to answer is: does an additional cooling to 35°C result in a benefit on clinical outcome ? Participants receive immediate cooling using a noninvasive transnasal cooling technique (RhonoChill) and are maintained at 35°C for 6 hours after reopening of the vessel using surface cooling, and then slowly rewarmed.\n\nResearchers will compare the intervention group (hypothermia and endovascular treatment and best medical treatment including iv thrombolysis) and control group (only endovascular treatment and best medical treatment including iv thrombolysis) to see if additional hypothermia leads to a better outcome after 3 months without relevant complications.",[277,28,118],[468,469],"hypothermia","neuroprotection","2025-01-02",{"date":472,"type":39},"2025-01-06",{"date":474,"type":39},"2024-07-07",{"date":476,"type":21},"2026-06-18",{"name":478,"class":45},"University of Freiburg",{"id":480,"slug":481,"hasResults":11,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":485,"eligibilityCriteria":486,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":488,"conditions":489,"keywords":492,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":503},"100571957","rescue-stenting-and-intravenous-thrombolysis-in-patients-with-large-vessel-ischemic-stroke-100571957","NCT06727006","Rescue Stenting and Intravenous Thrombolysis In Patients With Large Vessel Ischemic Stroke","Stroke, Thrombolysis and Rescue Stenting","STARS","Inclusion Criteria:\n\n* Patients with large vessel occlusion strokes undergoing thrombectomy and rescue stenting within 24 hours of stroke onset\n* Patients ≥ 18 years of age\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years\n* Refusal to give informed consent",{"count":463,"type":21},"Intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are the standard of care for treating selected patients with acute large-vessel occlusion stroke (LVOS). Successful revascularization is strongly correlated with favorable outcomes. Nevertheless, recanalization failure with stent retrieval and contact aspiration has been observed in up to 29% of patients. If primary thrombectomy fails to achieve recanalization, rescue stenting (RS) has proven to be a feasible rescue therapy. Currently, approved evidence-based alternatives for LVOS patients who have failed MT are lacking, but permanent stenting is suggested as a rescue treatment in expert consensus statements.\n\nDual antiplatelet therapy (DAPT), typically consisting of clopidogrel and aspirin, is recommended after stent implantation to reduce the risk of stent thrombosis; however, these medications are not suitable in the acute setting, and optimal platelet inhibition strategies remain unclear. Glycoprotein (GP) IIb\u002FIIIa receptor inhibitors have intravenous administration, a rapid onset of action, and their effects subside within a few hours after discontinuation. For these reasons, an increasing number of studies have investigated their use in conjunction with primary stenting for acute stroke. Currently, there is no evidence supporting the superiority of any particular antithrombotic strategy, so decisions are guided by clinical judgment.\n\nAn additional challenge for clinicians arises when IVT is combined with stenting. Stroke guidelines recommend starting antiplatelets 24 hours after IVT and the risk associated with antithrombotic therapy within the first 24 hours after IVT remains uncertain.\n\nThis is multicenter, prospective, observational study of patients with LVOS undergoing mechanical thrombectomy and rescue stenting. The aim of this study is to evaluate real-world antithrombotic strategies in emergency stenting, particularly in patients treated with IVT, and to assess the safety of emergent stenting following intravenous thrombolysis.",[28,490,356,491],"Stroke Acute","Rescue Stenting",[493,356],"Rescue stenting","2024-12-14",{"date":496,"type":39},"2024-12-17",{"date":498,"type":39},"2023-10-21",{"date":500,"type":21},"2027-03",{"name":502,"class":45},"ASST Santi Paolo e Carlo",7,{"id":505,"slug":506,"hasResults":11,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":22,"phases":513,"briefSummary":514,"conditions":515,"keywords":517,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":525,"locationsCount":76},"100566376","thrombectomy-versus-best-medical-management-in-large-vessel-occlusion-stroke-patients-presenting-beyond-24-hours-and-with-presence-of-collateral-flow-on-ct-angiography-100566376","NCT06654375","Thrombectomy Versus Best Medical Management in Large Vessel Occlusion Stroke Patients Presenting Beyond 24 Hours and With Presence of Collateral Flow on CT Angiography","Thrombectomy Versus Best Medical Management in Large Vessel Occlusion Stroke Patients Presenting Beyond 24 Hours and With Presence of Collateral Flow on CT Angiography: A Multicentre, Open-label, Registry-linked, Randomised Controlled Trial","Inclusion Criteria:\n\n1. Confirmation of ICA or MCA-M1 occlusion, as detected by MRA or CTA, with carotid occlusions potentially occurring in either the cervical or intracranial regions, and the possibility of accompanying tandem MCA lesions.\n2. Demonstration of moderate to good collateral flow, as evidenced by CTA imaging.\n3. The patient must be aged 18 years or older.\n4. The baseline NIHSSS score is equal to or greater than 2, and this score remains equal to or greater than 2 immediately prior to randomization.\n5. Endovascular treatment can be initiated (via femoral puncture) within a window of 24 to 72 hours from the onset of the stroke. The onset of the stroke is defined as the time the patient was last known to be at their neurologic baseline (patients with wake-up strokes are eligible if they meet the aforementioned time constraints).\n6. There must be no significant pre-stroke disability, as indicated by a pre-baseline modified Rankin Scale score of 0-2.\n7. The patient must be willing and able to return for the protocol-required follow-up visits.\n8. The patient or their legally authorized representative must have signed the Informed Consent form.\n\nExclusion Criteria:\n\n1. The subject has a serious, advanced, or terminal illness (as determined by the investigator) or a life expectancy of less than six months.\n2. The subject has a pre-existing medical, neurological, or psychiatric disease that would interfere with neurological or functional evaluations, or is already participating in another drug or device study.\n3. The subject is pregnant.\n4. The subject has contraindications for both MRI and CT contrast that prevent an MRI or CT contrast perfusion study. The hospital's local standard criteria should be applied to determine if contraindications exist.\n5. The subject has a known allergy to iodine and has previously been refractory to pretreatment medications.\n6. The subject has been treated with tPA more than 4.5 hours after the last known well time.\n7. The subject has a known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or has recently undergone oral anticoagulant therapy with an INR greater than 3.\n8. The subject has symptoms consistent with stroke in multiple locations.\n9. The subject has seizures at stroke onset, which makes the diagnosis of stroke doubtful and precludes obtaining an accurate baseline NIHSS assessment.\n10. The subject has a baseline blood glucose level of less than 50mg\u002FdL (2.78 mmol) or greater than 400mg\u002FdL (22.20 mmol).\n11. The subject has a baseline platelet count of less than 50,000\u002FuL.\n12. The subject has severe, sustained hypertension (Systolic Blood Pressure \\>185 mmHg or Diastolic Blood Pressure \\>110 mmHg) that is not treatable with medications.\n13. The subject is currently participating in another investigational drug or device study or registry.\n14. The subject is presumed to have a septic embolus, suspicion of bacterial endocarditis, or cerebral vasculitis.\n15. The subject has had clot retrieval attempted using a neurothrombectomy device within 24 hours of symptom onset.",{"count":512,"type":21},350,[24],"The goal of this clinical trial is to investigate if endovascular treatment (EVT) can effectively treat patients with large vessel occlusion (LVO) who present beyond the typical 24-hour window after symptom onset. The main questions it aims to answer are:\n\n* Can EVT improve functional independence at 90 days for patients treated after 24 hours?\n* What is the safety profile of EVT in this delayed treatment group compared to best medical management (BMM)? Researchers will compare EVT outcomes in patients presenting after 24 hours to those receiving BMM to see if EVT offers significant benefits.\n\nParticipants will:\n\n* Receive either EVT or BMM based on their eligibility.\n* Undergo CT angiography to assess collateral circulation and to confirm the presence of LVO.\n* Be followed for 90 days to evaluate functional outcomes and safety measures.",[490,29,516,28],"Medical Treatment",[518,32,27],"CTA","2024-10-22",{"date":521,"type":39},"2024-10-23",{"date":523,"type":39},"2024-06-25",{"date":211,"type":21},{"name":526,"class":45},"Tianjin Huanhu Hospital",{"id":528,"slug":529,"hasResults":11,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":534,"targetDuration":420,"studyType":251,"phases":4,"briefSummary":536,"conditions":537,"keywords":540,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":76},"100551157","ischemic-post-conditioning-in-the-treatment-of-acute-ischemic-stroke-100551157","NCT06456437","Ischemic Post-conditioning in the Treatment of Acute Ischemic Stroke","Ischemic Post-conditioning in the Treatment of Acute Ischemic Stroke--a Multicenter, Prospective Cohort Study","Inclusion Criteria:\n\n* 1)Ischemic stroke confirmed by CT or MRI of the head;\n* 2\\) Large vessel occlusion confirmed by CTA or MRA of the head, including: intracranial internal carotid artery (ICA), middle cerebral artery (MCA M1\u002FM2), anterior cerebral artery (ACA A1\u002FA2), basilar artery (BA), vertebral artery (VA), and posterior cerebral artery (PCA P1\u002FP2);\n* 3\\) Recanalization of the occluded vessel at eTICI grade 2b\u002F3 as confirmed by DSA after thrombectomy;\n* 4)The patient\u002Flegally authorized representative has signed an informed consent form.\n\nExclusion Criteria:\n\n* 1\\) Inability to perform an MRI or CT scan for any reason;\n* 2）The patient has any condition that would interfere with neurologic assessment or psychiatric disorders;\n* 3）Stroke onset with seizures resulted in the inability to obtain an accurate NIHSS baseline;\n* 4）Pregnancy\n* 5）Other serious, advanced or terminal illness;",{"count":535,"type":21},200,"Post-ischemic adaptation is a physical brain protective treatment strategy in which an ischemic event in an organ or tissue is treated and blood flow is restored, and an ischemic stimulus is given to local tissues to induce the production of anti-ischemic damage factors and reduce the damage associated with reperfusion therapy . Relevant basic studies have confirmed that post-ischemic adaptation can reduce infarct volume and promote neurological function recovery in animal models of cerebral infarction. Therefore, it may be beneficial to the recovery of neurological function in patients with acute ischemic stroke undergoing mechanical thrombus extraction.\n\nBased on the above background, the use of a balloon to repeatedly dilate-contract at the original occlusion site after revascularization to block and restore arterial flow may be an effective cerebroprotective treatment for patients with large-vessel occlusion who undergo thrombolysis. However, can this approach be safely used in patients with acute ischemic stroke treated with thrombolysis? What is the protocol for the length of time patients can tolerate post-ischemic adaptation? The application of this method in the treatment of acute ischemic stroke will be explored in this study.",[27,28,538,539],"Intracranial Artery Occlusion With Cerebral Infarction","Endovascular Treatments",[541,179,542,543,544],"Endovascular treatments","Retrieved clots","Ischemic Post-conditioning","Stroke etiology","2024-06-07",{"date":547,"type":39},"2024-06-13",{"date":549,"type":39},"2021-11-01",{"date":551,"type":21},"2025-12-31",{"name":553,"class":45},"Ming Wei",{"id":555,"slug":556,"hasResults":11,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":564,"conditions":565,"keywords":566,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":76},"100531511","triage-of-patients-presenting-beyond-24-hours-with-acute-ischemic-stroke-due-to-large-vessel-occlusions-track-lvo-late-100531511","NCT06200753","Triage of Patients Presenting Beyond 24 Hours With Acute Ischemic Stroke Due to Large Vessel Occlusions (TRACK-LVO Late)","Triage of Patients Presenting Beyond 24 Hours From Last Known Well With Acute Ischemic Stroke Due to Large Vessel Occlusions (TRACK-LVO Late): a TRACK-LVO Registry-linked Cohort","TRACK-LVO Late","Inclusion Criteria:\n\n* Patient admitted from Jan. 1st 2018 to Jan. 1st 2028;\n* Presenting beyond 24 hours from last known well;\n* Ischemic stroke confirmed by head CT or MRI;\n* Large vessel occlusion confirmed by head CTA or MRA: intracranial internal carotid artery (ICA), middle cerebral artery (MCA M1\u002FM2), anterior cerebral artery (ACA A1\u002FA2), basilar artery (BA), vertebral artery (VA), and posterior cerebral artery (PCA P1\u002FP2);\n* Patients receiving either endovascular therapy or best medical treatment.\n\nExclusion Criteria:\n\n• Presence of any forms of cerebral hemorrhage on CT\u002FMR at admission.",{"count":563,"type":21},1000,"The objective of this study is to create a comprehensive, multi-center, TRACK-LVO registry-linked cohort of consecutive patients with acute ischemic stroke (AIS) caused by large vessel occlusions (LVO) and presenting to each participating center beyond 24 hours from last known well, who are treated with either endovascular therapy (EVT) or the best available medical management (BMM).",[32,28,27],[567],"Acute Ischemic Stroke, Endovascular Therapy,","2023-12-30",{"date":570,"type":39},"2024-01-11",{"date":572,"type":39},"2018-01-01",{"date":574,"type":21},"2028-12-31",{"name":526,"class":45},{"id":577,"slug":578,"hasResults":11,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":584,"targetDuration":586,"studyType":251,"phases":4,"briefSummary":587,"conditions":588,"keywords":590,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":596,"leadSponsor":597,"locationsCount":598},"100489902","triage-of-patients-with-acute-ischemic-stroke-due-to-large-vessel-occlusions-2-100489902","NCT05659160","Triage of Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions-2","Triage of Patients With Acute Ischemic Stroke Due to Large Vessel Occlusions-2 (TRACK-LVO-2): an Imaging-based Patient Registry Study","TRACK-LVO-2","Inclusion Criteria:\n\n1. Patient admitted from Jan. 1st 2018 to Jan. 1st 2028;\n2. Age ≥ 18;\n3. Ischemic stroke confirmed by head CT or MRI;\n4. Large vessel occlusion confirmed by head CTA or MRA: intracranial internal carotid artery (ICA), middle cerebral artery (MCA M1\u002FM2), anterior cerebral artery (ACA A1\u002FA2), basilar artery (BA), vertebral artery (VA), and posterior cerebral artery (PCA P1\u002FP2);\n5. Patients receiving either endovascular therapy or best medical treatment;\n\nExclusion Criteria:\n\n\\- None",{"count":585,"type":21},5000,"1 Year","The objective of this study is to create a comprehensive, real-world, multi-center observational registry of consecutive patients admitted to hospitals with acute ischemic stroke (AIS) caused by large vessel occlusions (LVO), who are treated with either endovascular therapy (EVT) or the best available medical management (BMM).",[589,145,28],"Stroke, Acute Ischemic",[27,591,28],"Endovascular Therapy","2023-11-28",{"date":594,"type":39},"2023-12-01",{"date":549,"type":39},{"date":574,"type":21},{"name":526,"class":45},4]